United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
United Therapeutics Corp. (UTHR) PT Raised to $235 at Cowen
August 4, 2021 12:22 PM EDTCowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $235.00 (from $230.00) while maintaining an Outperform rating following results.
The analyst commented, "Q2 financials came in above consensus expectations on the top and bottom line, supported by strong performance from... More
United Therapeutics (UTHR) Tops Q2 EPS by $1.07
August 4, 2021 6:09 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More